beta-D-glucopyranose spirohydantoin

Beta-D-glucopyranose spirohydantoin is a synthetic small molecule and a glucose analogue designed as an experimental inhibitor of glycogen phosphorylase. It acts by binding at the catalytic site of the muscle form of glycogen phosphorylase (GP), thereby inhibiting its activity and blocking glycogenolysis. Structural studies show that this compound forms direct and water-mediated hydrogen bonds with GP and induces conformational changes in key protein loops involved in substrate access to the active site. The hydantoin moiety enhances affinity for GP compared to glucose itself by exploiting specific interactions within the enzyme's catalytic pocket. This compound has been used primarily as a research tool for studying carbohydrate metabolism and potential therapeutic modulation of blood glucose levels but has not advanced beyond preclinical or early investigative stages[1][2][3][6].

Other names

(5S,7R,8S,9S,10R)-8,9,10-trihydroxy-7-(hydroxymethyl)-6-oxa-1,3-diazaspiro[4.5]decane-2,4-dione1beta,1-(Iminocarbonyliminocarbonyl)-1-deoxy-D-glucopyranose